PMC:7105881 / 51529-52985 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1629","span":{"begin":1013,"end":1018},"obj":"Gene"},{"id":"1630","span":{"begin":93,"end":97},"obj":"Species"},{"id":"1631","span":{"begin":133,"end":141},"obj":"Species"},{"id":"1632","span":{"begin":179,"end":183},"obj":"Species"},{"id":"1633","span":{"begin":270,"end":274},"obj":"Species"},{"id":"1634","span":{"begin":334,"end":342},"obj":"Species"},{"id":"1635","span":{"begin":418,"end":426},"obj":"Species"},{"id":"1636","span":{"begin":531,"end":540},"obj":"Species"},{"id":"1637","span":{"begin":541,"end":547},"obj":"Species"},{"id":"1638","span":{"begin":594,"end":602},"obj":"Species"},{"id":"1639","span":{"begin":656,"end":663},"obj":"Species"},{"id":"1640","span":{"begin":907,"end":915},"obj":"Species"},{"id":"1641","span":{"begin":1030,"end":1034},"obj":"Species"},{"id":"1642","span":{"begin":1043,"end":1051},"obj":"Species"},{"id":"1643","span":{"begin":1208,"end":1216},"obj":"Species"},{"id":"1644","span":{"begin":1220,"end":1227},"obj":"Species"},{"id":"1645","span":{"begin":1437,"end":1445},"obj":"Species"},{"id":"1646","span":{"begin":895,"end":906},"obj":"Species"},{"id":"1647","span":{"begin":188,"end":206},"obj":"Chemical"},{"id":"1648","span":{"begin":454,"end":459},"obj":"Chemical"},{"id":"1649","span":{"begin":365,"end":383},"obj":"Disease"},{"id":"1650","span":{"begin":712,"end":727},"obj":"Disease"},{"id":"1651","span":{"begin":764,"end":777},"obj":"Disease"}],"attributes":[{"id":"A1629","pred":"tao:has_database_id","subj":"1629","obj":"Gene:1803"},{"id":"A1630","pred":"tao:has_database_id","subj":"1630","obj":"Tax:10090"},{"id":"A1631","pred":"tao:has_database_id","subj":"1631","obj":"Tax:1335626"},{"id":"A1632","pred":"tao:has_database_id","subj":"1632","obj":"Tax:10090"},{"id":"A1633","pred":"tao:has_database_id","subj":"1633","obj":"Tax:10090"},{"id":"A1634","pred":"tao:has_database_id","subj":"1634","obj":"Tax:1335626"},{"id":"A1635","pred":"tao:has_database_id","subj":"1635","obj":"Tax:1335626"},{"id":"A1636","pred":"tao:has_database_id","subj":"1636","obj":"Tax:9838"},{"id":"A1637","pred":"tao:has_database_id","subj":"1637","obj":"Tax:9838"},{"id":"A1638","pred":"tao:has_database_id","subj":"1638","obj":"Tax:1335626"},{"id":"A1639","pred":"tao:has_database_id","subj":"1639","obj":"Tax:30538"},{"id":"A1640","pred":"tao:has_database_id","subj":"1640","obj":"Tax:1335626"},{"id":"A1641","pred":"tao:has_database_id","subj":"1641","obj":"Tax:10090"},{"id":"A1642","pred":"tao:has_database_id","subj":"1642","obj":"Tax:1335626"},{"id":"A1643","pred":"tao:has_database_id","subj":"1643","obj":"Tax:1335626"},{"id":"A1644","pred":"tao:has_database_id","subj":"1644","obj":"Tax:9986"},{"id":"A1645","pred":"tao:has_database_id","subj":"1645","obj":"Tax:1335626"},{"id":"A1646","pred":"tao:has_database_id","subj":"1646","obj":"Tax:575864"},{"id":"A1647","pred":"tao:has_database_id","subj":"1647","obj":"MESH:C012714"},{"id":"A1648","pred":"tao:has_database_id","subj":"1648","obj":"MESH:C576871"},{"id":"A1649","pred":"tao:has_database_id","subj":"1649","obj":"MESH:D018352"},{"id":"A1650","pred":"tao:has_database_id","subj":"1650","obj":"MESH:D001102"},{"id":"A1651","pred":"tao:has_database_id","subj":"1651","obj":"MESH:D018352"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi (for mice) or aluminum phosphate (for NHPs) adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERS-CoV, protecting NHPs from MERS-CoV infection (Wang et al., 2015). In addition, MERS-CoV S1 protein adjuvanted with Advax and Sigma Adjuvant System induced low-titer neutralizing antibodies in dromedary camels with reduced and delayed viral shedding after MERS-CoV challenge, but high-titer neutralizing antibodies in alpacas with complete protection of viral shedding from viral infection, indicating that protection of MERS-CoV infection is positively correlated with serum neutralizing antibody titers (Adney et al., 2019). Moreover, immunization with a recombinant MERS-CoV NTD protein (rNTD) can induce neutralizing antibodies and cell-mediated responses, protecting Ad-hDPP4-transduced mice against MERS-CoV challenge (Jiaming et al., 2017). Notably, specific antibodies with neutralizing activity have been elicited by a S2 peptide sequence (residues 736–761) of MERS-CoV in rabbits (Yang et al., 2014a), but the protective efficacy of this peptide vaccine is unknown. The above reports demonstrate the potential for the development of MERS subunit vaccines based on the non-RBD fragments of MERS-CoV S protein."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T295","span":{"begin":45,"end":52},"obj":"Body_part"},{"id":"T296","span":{"begin":145,"end":152},"obj":"Body_part"},{"id":"T297","span":{"begin":430,"end":437},"obj":"Body_part"},{"id":"T298","span":{"begin":808,"end":813},"obj":"Body_part"},{"id":"T299","span":{"begin":827,"end":835},"obj":"Body_part"},{"id":"T300","span":{"begin":920,"end":927},"obj":"Body_part"},{"id":"T301","span":{"begin":974,"end":978},"obj":"Body_part"},{"id":"T302","span":{"begin":1448,"end":1455},"obj":"Body_part"}],"attributes":[{"id":"A295","pred":"fma_id","subj":"T295","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A296","pred":"fma_id","subj":"T296","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A297","pred":"fma_id","subj":"T297","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A298","pred":"fma_id","subj":"T298","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A299","pred":"fma_id","subj":"T299","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A300","pred":"fma_id","subj":"T300","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A301","pred":"fma_id","subj":"T301","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A302","pred":"fma_id","subj":"T302","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi (for mice) or aluminum phosphate (for NHPs) adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERS-CoV, protecting NHPs from MERS-CoV infection (Wang et al., 2015). In addition, MERS-CoV S1 protein adjuvanted with Advax and Sigma Adjuvant System induced low-titer neutralizing antibodies in dromedary camels with reduced and delayed viral shedding after MERS-CoV challenge, but high-titer neutralizing antibodies in alpacas with complete protection of viral shedding from viral infection, indicating that protection of MERS-CoV infection is positively correlated with serum neutralizing antibody titers (Adney et al., 2019). Moreover, immunization with a recombinant MERS-CoV NTD protein (rNTD) can induce neutralizing antibodies and cell-mediated responses, protecting Ad-hDPP4-transduced mice against MERS-CoV challenge (Jiaming et al., 2017). Notably, specific antibodies with neutralizing activity have been elicited by a S2 peptide sequence (residues 736–761) of MERS-CoV in rabbits (Yang et al., 2014a), but the protective efficacy of this peptide vaccine is unknown. The above reports demonstrate the potential for the development of MERS subunit vaccines based on the non-RBD fragments of MERS-CoV S protein."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T18","span":{"begin":808,"end":813},"obj":"Body_part"}],"attributes":[{"id":"A18","pred":"uberon_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi (for mice) or aluminum phosphate (for NHPs) adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERS-CoV, protecting NHPs from MERS-CoV infection (Wang et al., 2015). In addition, MERS-CoV S1 protein adjuvanted with Advax and Sigma Adjuvant System induced low-titer neutralizing antibodies in dromedary camels with reduced and delayed viral shedding after MERS-CoV challenge, but high-titer neutralizing antibodies in alpacas with complete protection of viral shedding from viral infection, indicating that protection of MERS-CoV infection is positively correlated with serum neutralizing antibody titers (Adney et al., 2019). Moreover, immunization with a recombinant MERS-CoV NTD protein (rNTD) can induce neutralizing antibodies and cell-mediated responses, protecting Ad-hDPP4-transduced mice against MERS-CoV challenge (Jiaming et al., 2017). Notably, specific antibodies with neutralizing activity have been elicited by a S2 peptide sequence (residues 736–761) of MERS-CoV in rabbits (Yang et al., 2014a), but the protective efficacy of this peptide vaccine is unknown. The above reports demonstrate the potential for the development of MERS subunit vaccines based on the non-RBD fragments of MERS-CoV S protein."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T258","span":{"begin":374,"end":383},"obj":"Disease"},{"id":"T259","span":{"begin":712,"end":727},"obj":"Disease"},{"id":"T260","span":{"begin":718,"end":727},"obj":"Disease"},{"id":"T261","span":{"begin":768,"end":777},"obj":"Disease"},{"id":"T262","span":{"begin":916,"end":919},"obj":"Disease"}],"attributes":[{"id":"A258","pred":"mondo_id","subj":"T258","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A259","pred":"mondo_id","subj":"T259","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A260","pred":"mondo_id","subj":"T260","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A261","pred":"mondo_id","subj":"T261","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A262","pred":"mondo_id","subj":"T262","obj":"http://purl.obolibrary.org/obo/MONDO_0008449"},{"id":"A263","pred":"mondo_id","subj":"T262","obj":"http://purl.obolibrary.org/obo/MONDO_0018075"}],"text":"MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi (for mice) or aluminum phosphate (for NHPs) adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERS-CoV, protecting NHPs from MERS-CoV infection (Wang et al., 2015). In addition, MERS-CoV S1 protein adjuvanted with Advax and Sigma Adjuvant System induced low-titer neutralizing antibodies in dromedary camels with reduced and delayed viral shedding after MERS-CoV challenge, but high-titer neutralizing antibodies in alpacas with complete protection of viral shedding from viral infection, indicating that protection of MERS-CoV infection is positively correlated with serum neutralizing antibody titers (Adney et al., 2019). Moreover, immunization with a recombinant MERS-CoV NTD protein (rNTD) can induce neutralizing antibodies and cell-mediated responses, protecting Ad-hDPP4-transduced mice against MERS-CoV challenge (Jiaming et al., 2017). Notably, specific antibodies with neutralizing activity have been elicited by a S2 peptide sequence (residues 736–761) of MERS-CoV in rabbits (Yang et al., 2014a), but the protective efficacy of this peptide vaccine is unknown. The above reports demonstrate the potential for the development of MERS subunit vaccines based on the non-RBD fragments of MERS-CoV S protein."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T625","span":{"begin":111,"end":114},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T626","span":{"begin":131,"end":132},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T627","span":{"begin":142,"end":144},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T628","span":{"begin":427,"end":429},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T629","span":{"begin":541,"end":547},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9837"},{"id":"T630","span":{"begin":893,"end":894},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T631","span":{"begin":974,"end":978},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T632","span":{"begin":1133,"end":1141},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T633","span":{"begin":1164,"end":1165},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T634","span":{"begin":1166,"end":1168},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T635","span":{"begin":1166,"end":1168},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"},{"id":"T636","span":{"begin":1169,"end":1176},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T637","span":{"begin":1286,"end":1293},"obj":"http://purl.obolibrary.org/obo/PR_000018263"}],"text":"MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi (for mice) or aluminum phosphate (for NHPs) adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERS-CoV, protecting NHPs from MERS-CoV infection (Wang et al., 2015). In addition, MERS-CoV S1 protein adjuvanted with Advax and Sigma Adjuvant System induced low-titer neutralizing antibodies in dromedary camels with reduced and delayed viral shedding after MERS-CoV challenge, but high-titer neutralizing antibodies in alpacas with complete protection of viral shedding from viral infection, indicating that protection of MERS-CoV infection is positively correlated with serum neutralizing antibody titers (Adney et al., 2019). Moreover, immunization with a recombinant MERS-CoV NTD protein (rNTD) can induce neutralizing antibodies and cell-mediated responses, protecting Ad-hDPP4-transduced mice against MERS-CoV challenge (Jiaming et al., 2017). Notably, specific antibodies with neutralizing activity have been elicited by a S2 peptide sequence (residues 736–761) of MERS-CoV in rabbits (Yang et al., 2014a), but the protective efficacy of this peptide vaccine is unknown. The above reports demonstrate the potential for the development of MERS subunit vaccines based on the non-RBD fragments of MERS-CoV S protein."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T7311","span":{"begin":45,"end":52},"obj":"Chemical"},{"id":"T57132","span":{"begin":145,"end":152},"obj":"Chemical"},{"id":"T57819","span":{"begin":188,"end":196},"obj":"Chemical"},{"id":"T80718","span":{"begin":197,"end":206},"obj":"Chemical"},{"id":"T17955","span":{"begin":218,"end":226},"obj":"Chemical"},{"id":"T31295","span":{"begin":430,"end":437},"obj":"Chemical"},{"id":"T49139","span":{"begin":920,"end":927},"obj":"Chemical"},{"id":"T12977","span":{"begin":1166,"end":1168},"obj":"Chemical"},{"id":"T4610","span":{"begin":1169,"end":1176},"obj":"Chemical"},{"id":"T3633","span":{"begin":1286,"end":1293},"obj":"Chemical"},{"id":"T63120","span":{"begin":1448,"end":1455},"obj":"Chemical"}],"attributes":[{"id":"A34114","pred":"chebi_id","subj":"T7311","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A63607","pred":"chebi_id","subj":"T57132","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A89318","pred":"chebi_id","subj":"T57819","obj":"http://purl.obolibrary.org/obo/CHEBI_28984"},{"id":"A80348","pred":"chebi_id","subj":"T80718","obj":"http://purl.obolibrary.org/obo/CHEBI_18367"},{"id":"A68051","pred":"chebi_id","subj":"T80718","obj":"http://purl.obolibrary.org/obo/CHEBI_26020"},{"id":"A98442","pred":"chebi_id","subj":"T80718","obj":"http://purl.obolibrary.org/obo/CHEBI_35780"},{"id":"A29408","pred":"chebi_id","subj":"T80718","obj":"http://purl.obolibrary.org/obo/CHEBI_43474"},{"id":"A14421","pred":"chebi_id","subj":"T17955","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"},{"id":"A59096","pred":"chebi_id","subj":"T31295","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A67089","pred":"chebi_id","subj":"T49139","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A29436","pred":"chebi_id","subj":"T12977","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"},{"id":"A77781","pred":"chebi_id","subj":"T4610","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A50406","pred":"chebi_id","subj":"T3633","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A69742","pred":"chebi_id","subj":"T63120","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi (for mice) or aluminum phosphate (for NHPs) adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERS-CoV, protecting NHPs from MERS-CoV infection (Wang et al., 2015). In addition, MERS-CoV S1 protein adjuvanted with Advax and Sigma Adjuvant System induced low-titer neutralizing antibodies in dromedary camels with reduced and delayed viral shedding after MERS-CoV challenge, but high-titer neutralizing antibodies in alpacas with complete protection of viral shedding from viral infection, indicating that protection of MERS-CoV infection is positively correlated with serum neutralizing antibody titers (Adney et al., 2019). Moreover, immunization with a recombinant MERS-CoV NTD protein (rNTD) can induce neutralizing antibodies and cell-mediated responses, protecting Ad-hDPP4-transduced mice against MERS-CoV challenge (Jiaming et al., 2017). Notably, specific antibodies with neutralizing activity have been elicited by a S2 peptide sequence (residues 736–761) of MERS-CoV in rabbits (Yang et al., 2014a), but the protective efficacy of this peptide vaccine is unknown. The above reports demonstrate the potential for the development of MERS subunit vaccines based on the non-RBD fragments of MERS-CoV S protein."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T105","span":{"begin":573,"end":587},"obj":"http://purl.obolibrary.org/obo/GO_0019076"},{"id":"T106","span":{"begin":692,"end":706},"obj":"http://purl.obolibrary.org/obo/GO_0019076"},{"id":"T107","span":{"begin":712,"end":727},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi (for mice) or aluminum phosphate (for NHPs) adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERS-CoV, protecting NHPs from MERS-CoV infection (Wang et al., 2015). In addition, MERS-CoV S1 protein adjuvanted with Advax and Sigma Adjuvant System induced low-titer neutralizing antibodies in dromedary camels with reduced and delayed viral shedding after MERS-CoV challenge, but high-titer neutralizing antibodies in alpacas with complete protection of viral shedding from viral infection, indicating that protection of MERS-CoV infection is positively correlated with serum neutralizing antibody titers (Adney et al., 2019). Moreover, immunization with a recombinant MERS-CoV NTD protein (rNTD) can induce neutralizing antibodies and cell-mediated responses, protecting Ad-hDPP4-transduced mice against MERS-CoV challenge (Jiaming et al., 2017). Notably, specific antibodies with neutralizing activity have been elicited by a S2 peptide sequence (residues 736–761) of MERS-CoV in rabbits (Yang et al., 2014a), but the protective efficacy of this peptide vaccine is unknown. The above reports demonstrate the potential for the development of MERS subunit vaccines based on the non-RBD fragments of MERS-CoV S protein."}

{"project":"2_test","denotations":[{"id":"32265848-26218507-36511221","span":{"begin":398,"end":402},"obj":"26218507"},{"id":"32265848-30832356-36511222","span":{"begin":858,"end":862},"obj":"30832356"},{"id":"32265848-27899228-36511223","span":{"begin":1079,"end":1083},"obj":"27899228"}],"text":"MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi (for mice) or aluminum phosphate (for NHPs) adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERS-CoV, protecting NHPs from MERS-CoV infection (Wang et al., 2015). In addition, MERS-CoV S1 protein adjuvanted with Advax and Sigma Adjuvant System induced low-titer neutralizing antibodies in dromedary camels with reduced and delayed viral shedding after MERS-CoV challenge, but high-titer neutralizing antibodies in alpacas with complete protection of viral shedding from viral infection, indicating that protection of MERS-CoV infection is positively correlated with serum neutralizing antibody titers (Adney et al., 2019). Moreover, immunization with a recombinant MERS-CoV NTD protein (rNTD) can induce neutralizing antibodies and cell-mediated responses, protecting Ad-hDPP4-transduced mice against MERS-CoV challenge (Jiaming et al., 2017). Notably, specific antibodies with neutralizing activity have been elicited by a S2 peptide sequence (residues 736–761) of MERS-CoV in rabbits (Yang et al., 2014a), but the protective efficacy of this peptide vaccine is unknown. The above reports demonstrate the potential for the development of MERS subunit vaccines based on the non-RBD fragments of MERS-CoV S protein."}

{"project":"LitCovid-sentences","denotations":[{"id":"T281","span":{"begin":0,"end":107},"obj":"Sentence"},{"id":"T282","span":{"begin":108,"end":404},"obj":"Sentence"},{"id":"T283","span":{"begin":405,"end":864},"obj":"Sentence"},{"id":"T284","span":{"begin":865,"end":1085},"obj":"Sentence"},{"id":"T285","span":{"begin":1086,"end":1313},"obj":"Sentence"},{"id":"T286","span":{"begin":1314,"end":1456},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi (for mice) or aluminum phosphate (for NHPs) adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERS-CoV, protecting NHPs from MERS-CoV infection (Wang et al., 2015). In addition, MERS-CoV S1 protein adjuvanted with Advax and Sigma Adjuvant System induced low-titer neutralizing antibodies in dromedary camels with reduced and delayed viral shedding after MERS-CoV challenge, but high-titer neutralizing antibodies in alpacas with complete protection of viral shedding from viral infection, indicating that protection of MERS-CoV infection is positively correlated with serum neutralizing antibody titers (Adney et al., 2019). Moreover, immunization with a recombinant MERS-CoV NTD protein (rNTD) can induce neutralizing antibodies and cell-mediated responses, protecting Ad-hDPP4-transduced mice against MERS-CoV challenge (Jiaming et al., 2017). Notably, specific antibodies with neutralizing activity have been elicited by a S2 peptide sequence (residues 736–761) of MERS-CoV in rabbits (Yang et al., 2014a), but the protective efficacy of this peptide vaccine is unknown. The above reports demonstrate the potential for the development of MERS subunit vaccines based on the non-RBD fragments of MERS-CoV S protein."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T824","span":{"begin":0,"end":4},"obj":"SP_9"},{"id":"T825","span":{"begin":43,"end":52},"obj":"PG_1"},{"id":"T826","span":{"begin":93,"end":97},"obj":"NCBITaxon:10088"},{"id":"T827","span":{"begin":133,"end":141},"obj":"SP_9"},{"id":"T828","span":{"begin":179,"end":183},"obj":"NCBITaxon:10088"},{"id":"T829","span":{"begin":197,"end":206},"obj":"CHEBI:18367;CHEBI:18367"},{"id":"T830","span":{"begin":218,"end":226},"obj":"CHEBI:60809;CHEBI:60809"},{"id":"T831","span":{"begin":256,"end":266},"obj":"GO:0042571"},{"id":"T832","span":{"begin":270,"end":274},"obj":"NCBITaxon:10088"},{"id":"T833","span":{"begin":334,"end":342},"obj":"SP_9"},{"id":"T834","span":{"begin":365,"end":373},"obj":"SP_9"},{"id":"T835","span":{"begin":418,"end":426},"obj":"SP_9"},{"id":"T836","span":{"begin":438,"end":448},"obj":"CHEBI:60809;CHEBI:60809"},{"id":"T837","span":{"begin":470,"end":478},"obj":"CHEBI:60809;CHEBI:60809"},{"id":"T838","span":{"begin":517,"end":527},"obj":"GO:0042571"},{"id":"T839","span":{"begin":531,"end":540},"obj":"SP_3"},{"id":"T840","span":{"begin":573,"end":578},"obj":"NCBITaxon:10239"},{"id":"T841","span":{"begin":594,"end":602},"obj":"SP_9"},{"id":"T842","span":{"begin":642,"end":652},"obj":"GO:0042571"},{"id":"T843","span":{"begin":692,"end":697},"obj":"NCBITaxon:10239"},{"id":"T844","span":{"begin":712,"end":717},"obj":"NCBITaxon:10239"},{"id":"T845","span":{"begin":759,"end":767},"obj":"SP_9"},{"id":"T846","span":{"begin":808,"end":813},"obj":"UBERON:0001977"},{"id":"T847","span":{"begin":827,"end":835},"obj":"GO:0042571"},{"id":"T848","span":{"begin":907,"end":915},"obj":"SP_9"},{"id":"T849","span":{"begin":959,"end":969},"obj":"GO:0042571"},{"id":"T850","span":{"begin":1013,"end":1018},"obj":"PR:P27487"},{"id":"T851","span":{"begin":1019,"end":1029},"obj":"GO:0009293"},{"id":"T852","span":{"begin":1030,"end":1034},"obj":"NCBITaxon:10088"},{"id":"T853","span":{"begin":1043,"end":1051},"obj":"SP_9"},{"id":"T854","span":{"begin":1104,"end":1114},"obj":"GO:0042571"},{"id":"T855","span":{"begin":1208,"end":1216},"obj":"SP_9"},{"id":"T856","span":{"begin":1220,"end":1227},"obj":"NCBITaxon:9986"},{"id":"T857","span":{"begin":1381,"end":1385},"obj":"SP_9"},{"id":"T858","span":{"begin":1437,"end":1445},"obj":"SP_9"},{"id":"T859","span":{"begin":1446,"end":1455},"obj":"PG_1"},{"id":"T62884","span":{"begin":0,"end":4},"obj":"SP_9"},{"id":"T86511","span":{"begin":43,"end":52},"obj":"PG_1"},{"id":"T41020","span":{"begin":93,"end":97},"obj":"NCBITaxon:10088"},{"id":"T40411","span":{"begin":133,"end":141},"obj":"SP_9"},{"id":"T37210","span":{"begin":179,"end":183},"obj":"NCBITaxon:10088"},{"id":"T41168","span":{"begin":197,"end":206},"obj":"CHEBI:18367;CHEBI:18367"},{"id":"T70226","span":{"begin":218,"end":226},"obj":"CHEBI:60809;CHEBI:60809"},{"id":"T92275","span":{"begin":256,"end":266},"obj":"GO:0042571"},{"id":"T79327","span":{"begin":270,"end":274},"obj":"NCBITaxon:10088"},{"id":"T83835","span":{"begin":334,"end":342},"obj":"SP_9"},{"id":"T51357","span":{"begin":365,"end":373},"obj":"SP_9"},{"id":"T49095","span":{"begin":418,"end":426},"obj":"SP_9"},{"id":"T41407","span":{"begin":438,"end":448},"obj":"CHEBI:60809;CHEBI:60809"},{"id":"T73205","span":{"begin":470,"end":478},"obj":"CHEBI:60809;CHEBI:60809"},{"id":"T42217","span":{"begin":517,"end":527},"obj":"GO:0042571"},{"id":"T2952","span":{"begin":531,"end":540},"obj":"SP_3"},{"id":"T82649","span":{"begin":573,"end":578},"obj":"NCBITaxon:10239"},{"id":"T89000","span":{"begin":594,"end":602},"obj":"SP_9"},{"id":"T40063","span":{"begin":642,"end":652},"obj":"GO:0042571"},{"id":"T61602","span":{"begin":692,"end":697},"obj":"NCBITaxon:10239"},{"id":"T77755","span":{"begin":712,"end":717},"obj":"NCBITaxon:10239"},{"id":"T3011","span":{"begin":759,"end":767},"obj":"SP_9"},{"id":"T25491","span":{"begin":808,"end":813},"obj":"UBERON:0001977"},{"id":"T61243","span":{"begin":827,"end":835},"obj":"GO:0042571"},{"id":"T77946","span":{"begin":907,"end":915},"obj":"SP_9"},{"id":"T14492","span":{"begin":959,"end":969},"obj":"GO:0042571"},{"id":"T69971","span":{"begin":1013,"end":1018},"obj":"PR:P27487"},{"id":"T61320","span":{"begin":1019,"end":1029},"obj":"GO:0009293"},{"id":"T91846","span":{"begin":1030,"end":1034},"obj":"NCBITaxon:10088"},{"id":"T23955","span":{"begin":1043,"end":1051},"obj":"SP_9"},{"id":"T87243","span":{"begin":1104,"end":1114},"obj":"GO:0042571"},{"id":"T44539","span":{"begin":1208,"end":1216},"obj":"SP_9"},{"id":"T16466","span":{"begin":1220,"end":1227},"obj":"NCBITaxon:9986"},{"id":"T51237","span":{"begin":1381,"end":1385},"obj":"SP_9"},{"id":"T36049","span":{"begin":1437,"end":1445},"obj":"SP_9"},{"id":"T16485","span":{"begin":1446,"end":1455},"obj":"PG_1"}],"text":"MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi (for mice) or aluminum phosphate (for NHPs) adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERS-CoV, protecting NHPs from MERS-CoV infection (Wang et al., 2015). In addition, MERS-CoV S1 protein adjuvanted with Advax and Sigma Adjuvant System induced low-titer neutralizing antibodies in dromedary camels with reduced and delayed viral shedding after MERS-CoV challenge, but high-titer neutralizing antibodies in alpacas with complete protection of viral shedding from viral infection, indicating that protection of MERS-CoV infection is positively correlated with serum neutralizing antibody titers (Adney et al., 2019). Moreover, immunization with a recombinant MERS-CoV NTD protein (rNTD) can induce neutralizing antibodies and cell-mediated responses, protecting Ad-hDPP4-transduced mice against MERS-CoV challenge (Jiaming et al., 2017). Notably, specific antibodies with neutralizing activity have been elicited by a S2 peptide sequence (residues 736–761) of MERS-CoV in rabbits (Yang et al., 2014a), but the protective efficacy of this peptide vaccine is unknown. The above reports demonstrate the potential for the development of MERS subunit vaccines based on the non-RBD fragments of MERS-CoV S protein."}